Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
IPO Year: 2018
Exchange: NASDAQ
Website: etonpharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/4/2024 | $9.00 | Buy | H.C. Wainwright |
5/6/2024 | $8.00 | Buy | Craig Hallum |
10/14/2021 | $10.00 | Buy | B. Riley Securities |
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The Company's presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET. Investors can access the presentation here. To schedule an in-person 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright. About Eton Pharmaceuticals Eton is an
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA dateQ2 2024 Cash Flow from Operations of $1.3 million, including the payment of one-time $2.0 million NDA filing fee for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, to
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in* (Audio Only)Click Here Webcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@et
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025. "The acceptance of our NDA is a
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2024. "We have had a very productive start to 2024. In addition to reporting record product sa
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows: Date:Monday, May 13, 2024 Time: 10:00am ET Webcast: Click Here To schedule a 1x1 meeting with the Company, please contact your Citizens JMP institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, Eton's proprietary patented formulation of hydrocortisone oral solution. The Company expects t
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has granted an exclusive license to Eton Pharmaceuticals, Inc. (NASDAQ:ETON) (Eton) for the commercialization of GOLIKE ® family of products in the United States. "This transition is fully aligned with Relief's strategy of moving the GOLIKE products into partnership models in the U.S. and Europe. We are very pleased to be establishing this partnership with Eton for GOLIKE patients in the U.S. given their
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
H.C. Wainwright resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Craig Hallum initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $8.00
B. Riley Securities resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $15.00 previously
10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K/A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
DEF 14A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 -
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $7.966 million which missed the analyst consensus estimate of $8.000 million by 0.43 percent. This is a 50.19 percent increase over sales of $5.304 million the same period last year.
Craig-Hallum analyst Chase Knickerbocker initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $8.
Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, Eton's proprietary patented formulation of hydrocortisone oral solution. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2025.
Gainers Biolase (NASDAQ:BIOL) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. The market value of their outstanding shares is at $4.6 million. The company's, Q4 earnings came out yesterday. Outlook Therapeutics (NASDAQ:OTLK) shares moved upwards by 46.73% to $10.33. The market value of their outstanding shares is at $222.9 million. Eton Pharmaceuticals (NASDAQ:ETON) shares rose 15.46% to $4.18. The market value of their outstanding shares is at $107.3 million. Monogram Orthopaedics (NASDAQ:MGRM) stock moved upwards by 13.15% to $2.58. The market value of their outstanding shares is at $81.6 million. Ontrak (NASDAQ:OTRK) shares increased by 11.49% to $0.29. The
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually
Eton Pharmaceuticals (NASDAQ:ETON) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Eton Pharmaceuticals missed estimated earnings by -125.0%, reporting an EPS of $-0.09 versus an estimate of $-0.04. Revenue was down $1.19 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.08 which was followed by a 15.0% drop in the share price the next day. Here's a look at Eton Pharmaceuticals's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.10 -0.09 -0.14 0.01 EPS Actual -0.02 0.18 -0.10 0.04 Revenue Estimate 6.26M 6.5
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 125 percent. The company reported quarterly sales of $7.313 million which missed the analyst consensus estimate of $7.700 million by 5.03 percent. This is a 13.94 percent decrease over sales of $8.498 million the same period last year.
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA) and assigned a February 28, 2025 PDUFA dateQ2 2024 Cash Flow from Operations of $1.3 million, including the payment of one-time $2.0 million NDA filing fee for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, to
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in* (Audio Only)Click Here Webcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@et
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2024. "We have had a very productive start to 2024. In addition to reporting record product sa
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022Announced successful results from ET-400's pivotal bioequivalence study, NDA submission planned for Q2 2024Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial resu
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eton
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on handAcquired ultra-rare disease product Nitisinone CapsulesManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2023.
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions t
Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine AnhydrousManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023. "With record product sales, the launch of Betaine Anhydrous, and positive cash flow and earnings, Eton's second quarter was exceptional
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adam